IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F - Wikidata - wikimedia - TriplyDB

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

http://www.wikidata.org/entity/Q35835653

about

IDH1 and IDH2 mutations in gliomas Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms Genetics of myeloproliferative neoplasms Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis One thousand patients with primary myelofibrosis: the mayo clinic experience.What do we know about IDH1/2 mutations so far, and how do we use it?What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.The future of epigenetic therapy in solid tumours--lessons from the past.Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.Emerging targeted therapies in myelofibrosis.Molecular biology of Philadelphia-negative myeloproliferative neoplasms Genetic and epigenetic alterations of myeloproliferative disorders.TET proteins: on the frenetic hunt for new cytosine modifications.The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.Isocitrate dehydrogenase mutations in leukemia.Genetic basis of MPN: Beyond JAK2-V617F.Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.Emerging drugs for the treatment of myelofibrosis.The evolution and clinical relevance of prognostic classification systems in myelofibrosis.IDH mutations in cancer and progress toward development of targeted therapeutics.Prognosis of Primary Myelofibrosis in the Genomic Era Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.The role of the extracellular matrix in primary myelofibrosis.Management of myelofibrosis: JAK inhibition and beyond.Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms.Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Identification of potential therapeutic target genes and miRNAs for primary myelofibrosis with microarray analysis.

P2860

Q24561928-2191785B-FA41-47E6-B08F-034481C62B2B Q26738514-EC5918A0-19D3-4009-AAD0-6DB907201B29 Q26766319-1CEC1AA4-2E51-4987-BF8B-00AA0B55AD82 Q26823651-B20DB8D5-10B9-4DC2-835B-2027610AD385 Q27853094-8717A5D4-68FF-4A90-850F-9E924E786FA5 Q33413428-5A1A3631-B815-4074-88DD-CBCE7DB09E18 Q33558154-8336CDFB-58B4-44BF-B5D3-E12742D922EA Q33769072-15644725-0336-4CCC-940C-117CD29F9D59 Q34037065-7ECCEB64-52E5-40D4-B9F6-394D0B6875CE Q34348505-4648A73E-F440-4906-86FB-06A3D86744AE Q34661033-DF16C89D-5497-48E8-9E38-1992A8C430D2 Q35995222-B14CE3BA-9E06-42D7-8C25-7F8DDDB7BE3A Q36364763-508B19A3-8959-4BD1-9933-2AC90C51EF92 Q36512816-B12308D8-8D65-4550-9438-CFEB8AA0C5E1 Q36788229-8A752946-ADD6-4EA7-9B52-EF082C770692 Q36832167-970E8EE6-9C18-4857-B1DF-3D866CDD0E51 Q37061554-1203CA9E-6B4C-4AF5-98C7-BFC7D7CD158D Q37432049-2D0C4C17-B55D-4E14-BB58-85C617324896 Q37548944-D736BD06-748D-456B-AEC7-A347E5D69A49 Q37956603-503887D1-B530-41AD-96EB-15F6B98C8D1A Q38018908-74D8DA63-50AA-4B33-9AA1-87ED078B2D0F Q38025160-44AF8D6B-B353-4667-BD42-F7AB36B6388D Q38050756-F4FD2628-136A-435B-9674-BC9717083341 Q38066786-1F30D5EA-3A34-4D68-B04C-D7B7F4425601 Q38102668-44BE31EA-9AA5-42DB-ABF4-034EF38D77F7 Q38121089-EF17A4C2-C4C7-4AA0-A5E9-8F192AC92AFD Q38133721-9C87BECB-4000-430F-8A1A-9826655A7F21 Q38159973-67BE0140-F522-407B-A0FD-94EDDF3979C2 Q38174781-FDC362F7-AB86-40F5-828F-662D1653E992 Q38187675-73351B8C-B242-4C90-ACDC-8E154B1689A2 Q38543775-6AAE52E1-56D8-4425-8E65-F4A5EC886DD2 Q38683077-8C8195E2-CDB2-4322-B88E-E1917762A605 Q38785528-73B800EE-A665-4F05-BE19-E82E13F5ECAE Q38926804-62DFFA0F-98D7-4381-BBD5-9280A9FA952C Q39015300-89A27E48-EE74-409F-BB95-1EFEB1F0D7BB Q39117766-08C53044-1729-4252-8EFC-598E6A74F0B9 Q39232415-0B7F7A37-AE2E-43CE-BCE5-A81F41458884 Q39482201-417FB81B-5DFF-4AE9-9E94-A6FE9C35C99D Q39869997-DF694DC8-1484-4A87-979F-92C46E1AB74D Q41665045-D81DB9D3-2C6F-4DE1-812A-F61CCAE1B24F

P2860

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

http://www.wikidata.org/entity/Q35835653

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

IDH mutations in primary myelo ...... c collaboration with JAK2V617F

@ast

IDH mutations in primary myelo ...... c collaboration with JAK2V617F

@en

type

label

IDH mutations in primary myelo ...... c collaboration with JAK2V617F

@ast

IDH mutations in primary myelo ...... c collaboration with JAK2V617F

@en

prefLabel

IDH mutations in primary myelo ...... c collaboration with JAK2V617F

@ast

IDH mutations in primary myelo ...... c collaboration with JAK2V617F

@en

P1433

Q35835653-7A1BE843-5F03-4246-AB06-A6375CC25BC3

P1476

Q35835653-6EC95C0C-B14D-429A-B108-82F8425E7222

P2093

Q35835653-25A66985-C82C-4DFC-BFFE-2B756CDB236D

Q35835653-61DAC8A3-8347-4662-9624-26D97FE3EA4A

Q35835653-817A8877-986F-411A-A84C-FA78D1B0B8D1

Q35835653-BAAE84B4-1EAB-4F4B-A104-E9CCBA8B2DE3

Q35835653-E780485D-49EF-4448-ADC3-06B019664CEC

Q35835653-E8F615F8-C15D-4BEF-8ABC-A90823A93814

Q35835653-FECC797C-030A-41D0-B904-652AE37DE4CA

P2860

Q35835653-01DC02A3-414D-42F3-8CC4-8DC0C7C54BB5

Q35835653-0D52992A-607F-468C-B9F4-D5710F88CC3A

Q35835653-0ECA9A0D-A27B-44B5-9C89-47C5FE2D9D60

Q35835653-13CDF804-7E3A-485C-BB26-32D47B519508

Q35835653-158355EF-6B5D-4599-9430-75208A6741E4

Q35835653-1C745003-4D36-4D71-A8D8-19446A495132

Q35835653-1E217C6A-71CB-47E8-B045-D0C28EC1AC80

Q35835653-2702399C-360B-48D3-A998-4685809716C3

Q35835653-2A5FA728-654F-480B-99A8-656FCD9F0C0F

Q35835653-2E0D7C16-1445-4191-A573-EB837970D282

P2888

Q35835653-7C66F4D8-F687-4A7C-BA5F-33A367B1BC8D

P304

Q35835653-7D03B5C5-9A49-4FF5-AA46-A82D21E9461F

P31

Q35835653-B69D4537-849C-4876-B865-AC98A4A86546

P356

Q35835653-0905C1E7-7597-4D7E-A890-72020E7DCC02

P433

Q35835653-37378E9F-1178-4209-BAD7-81AED17DAF5E

P478

Q35835653-A186935E-5CBC-4E9E-90FF-B2551524258C

P50

Q35835653-4C156BA5-77A3-45AD-96C7-ED6AF9B97080

P577

Q35835653-93CF5E15-232C-44B3-BD31-8CF1899541E9

P5875

Q35835653-5F64222F-6BF5-4890-8F0E-4D1F9010FF96

P6179

Q35835653-5B26646E-ACEA-454F-A200-FDA69A73A371

P698

Q35835653-A170F42E-ECC4-4C72-AFB1-043ADAEFB7C0

P921

Q35835653-3C7E7F5A-E326-43E0-9648-B3644B70C8C0

Q35835653-48398F56-0CB6-4727-97ED-F478EE336537

P932

Q35835653-9B4D70AA-D535-407D-AE52-33A5642B7553

P356

P1433

P1476

IDH mutations in primary myelo ...... c collaboration with JAK2V617F

@en

P2093

A Pardanani

http://www.w3.org/2001/XMLSchema#string

C M Finke

http://www.w3.org/2001/XMLSchema#string

N H Sulai

http://www.w3.org/2001/XMLSchema#string

R A Knudson

http://www.w3.org/2001/XMLSchema#string

R F McClure

http://www.w3.org/2001/XMLSchema#string

T Jimma

http://www.w3.org/2001/XMLSchema#string

T L Lasho

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Recurring mutations found by sequencing an acute myeloid leukemia genome

An integrated genomic analysis of human glioblastoma multiforme

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

P2888

P304

475-480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2011.253

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51632498

http://www.w3.org/2001/XMLSchema#string

P6179

1017042221

http://www.w3.org/2001/XMLSchema#string

P698

21912393

http://www.w3.org/2001/XMLSchema#string

P921

P932

3306137

http://www.w3.org/2001/XMLSchema#string